Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer

Cancer Science

Volumn 97, Issue 7, 2006, Pages 582-588

  Koukourakis, Michael I ^a   Giatromanolaki, Alexandra ^a   Polychronidis, Alexandros ^a   Simopoulos, Costantinos ^a   Gatter, Kevin C ^b   Harris, Adrian L ^c   Sivridis, Efthimios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; GLUCOSE TRANSPORTER 1; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; LACTATE DEHYDROGENASE; LACTIC ACID; OXYGEN; PROTEIN BNIP3; VASCULOTROPIN;

ACIDOSIS; ANAEROBIC METABOLISM; ANEMIA; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE ACTIVATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; ONCOGENE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; REGULATORY MECHANISM; UPREGULATION; VASCULARIZATION;

ADENOCARCINOMA; ANAEROBIOSIS; ANEMIA; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; ISOENZYMES; L-LACTATE DEHYDROGENASE; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745947446     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00220.x     Document Type: Article

References (47)

1. Brown JM. The hypoxic cell: A target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59: 5863-70.
2. Kumar P. Tumour hypoxia and anemia: Impact on the efficacy of radiation therapy. Semin Hematol 2000; 37 (4 Suppl. 6): 4-8.
3. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: Implications in radiotherapy? Int J Radiat Oncol Biol Phys 2000; 48: 545-53.
4. Chaplin DJ, Trotter MJ, Dougherty GJ. Microregional tumour blood flow: heterogeneity and therapeutic significance. In: Bicknell R, Lewis CE, Ferrara N, eds. Tumour Angiogenesis. Oxford: Oxford University Press, 1997; 61-70.
5. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
6. De Deken RH. The Crabtree effect: A regulatory system in yeast. J Gen Microbiol 1966; 44: 149-56.
7. Semenza GL, Jiang BH, Leung SW, Passantino R et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996; 271: 32529-37.
8. Ema M, Taya S, Yokotani N et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94: 4273-8.
9. Sowter HM, Ratcliffe PJ, Watson P et al. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 2001; 61: 6669-73.
10. Miyazaki K, Kawamoto T, Tanimoto K et al. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J Biol Chem 2002; 277: 47014-21.
11. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95: 7987-92.
12. Appelhoff RJ, Tian YM, Raval RR et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65.
13. Blancher C, Moore JW, Robertson N, Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 2001; 61: 7349-55.
14. Laughner E, Taghavi P, Chiles K et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
15. Raval RR, Lau KW, Tran MG et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-86.
16. Wang V, Davis DA, Haque M et al. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res 2005; 65: 3299-306.
17. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-90.
18. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 7992-8.
19. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Tumour and Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-85.
20. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Tumor oxygenation in anemic rats: Effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995; 34: 379-84.
21. Dische S. Radiotherapy and anaemia - the clinical experience. Radiother Oncol 1991; 20 (Suppl. 1): 35-40.
22. Semenza GL. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochem Pharmacol 2000; 59: 47-53.
23. Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. Mol Cancer 2003; 2: 31.
24. Suzuki K, Kizaki T, Hitomi Y et al. Genetic variation in hypoxia-inducible factor 1alpha and its possible association with high altitude adaptation in Sherpas. Med Hypotheses 2003; 61: 385-9.
25. Bardos JI, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004; 26: 262-9.
26. Hutchison GJ, Valentine HR, Loncaster JA et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004; 10: 8405-12.
27. Mayer A, Wree A, Hockel M et al. Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix. Cancer Res 2004; 64: 5876-81.
28. Discher DJ, Bishopric NH, Wu X et al. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 1998; 273: 26087-93.
29. Riera MF, Meroni SB, Pellizzari EH, Cigorraga SB. Assessment of the roles of mitogen-activated protein kinase and phosphatidyl inositol 3-kinase/protein kinase B pathways in the basic fibroblast growth factor regulation of Sertoli cell function. J Mol Endocrinol 2003; 31: 279-89.
30. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94: 6658-63.
31. Knies-Bamforth UE, Fox SB, Poulsom R et al. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004; 64: 6563-70.
32. Chen G, Cizeau J, Vande Velde C et al. Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem 1999; 274: 7-10.
33. Imazu T, Shimizu S, Tagami S et al. Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability. Oncogene 1999; 18: 4523-9.
34. Bruik RK. Expression of the gene encoding the proapoptotic BNIP3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000; 97: 9082-7.
35. Kothari S, Cizeau J, McMillan-Ward E et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003; 22: 4734-44.
36. Giatromanolaki A, Koukourakis MI, Sowter HM et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5566-71.
37. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
38. Wagner S, Hussain MZ, Hunt TK et al. Stimulation of fibroblast proliferation by lactate-mediated oxidants. Wound Repair Regen 2004; 12: 368-73.
39. Pouyssegur J, Franchi A, Pages G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 2001; 240: 186-96.
40. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role of tumor-associated stroma. Cancer Res 2006; 66: 632-7.
41. Shen M, Kawamoto T, Yan W et al. Molecular characterization of the novel basic helix-loop-helix protein DEC1 expressed in differentiated human embryo chondrocytes. Biochem Biophys Res Commun 1997; 236: 294-8.
42. Boudjelal M, Taneja R, Matsubara S et al. Overexpression of Stra13, a novel retinoic acid-inducible gene of the basic helix-loop-helix family, inhibits mesodermal and promotes neuronal differentiation of P19 cells. Genes Dev 1997; 11: 2052-65.
43. Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Regulation of STRA13 by the von Hippel-Lindau tumour suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J Biol Chem 2001; 276: 15306-15.
44. Koukourakis MI, Giatromanolaki A, Liberis V, Sivridis E. Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer. Anticancer Res 2002; 22: 4137-40.
45. Koukourakis MI, Giatromanolaki A, Sivridis E et al. Tumour and Angiogenesis Research Group. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 67-71.
46. Winter SC, Shah KA, Campo L et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 7614-20.
47. Hoogsteen IJ, Pop LA, Marres HA et al. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2006; 64: 83-9.